GLG News by Oncologists Specializing in Hematologic Malignancies in the U.S.

Millineum's Velcade is approved for relapsed/refractory MM and the comapny has relaesed information taht preliminary data from a phase III trial show efficacy in frontline treatment, Until more details are relaesed, Celgene's oral agents Revlimid and Talidomide dominate the use in frontline treatment....

This press release claims that Imclone's Erbitux increaseses overall survival when given in combination with Cisplatinum /venorelbine in patients with advanced lung cancer. The duration of increased survival is not provided and 2 months ago Erbitux was ineffective in combination with Taxanes/Carboplatinum...

    The company claims that Erbitux has shown survival benefit in lung cancer (NSCLC) in the current Phase III trial.  how much benefit? what are its implications? 

Humax-EGFr is an antibody targeting the EGF receptor.  Currently, Cetuximab, another EGFr antibody is approved for the treatment of patients with unresectable head and neck cancer.   Humax-EGFr could have a role in this disease if its efficacy is greater than or its toxicity profile is...

At present,  no biologic agents have been approved for the treatment of her-2 negative breast cancer.  The addition of Avastin to chemotherapy for patients with stage IV breast cancer has the potential to improve progression free survival and improve quality of life.  FDA approval of...

Genmab's Humax-Inflam is a humanized antibody against Interleukin-8 Early Phase Clinical trials showed some activity in patients with palmoplantar pastulosis , a dermatological inflammatory disorder Although IL-8 palys a role in angiogenesis, it is difficult to conceptaulize taht antibody against IL-8...

CTI's Pixantrone have shown efficacy in relapsed aggressive NHL and indolent NHL, mostly in studies involving small number of patients. Current trial will investigate if addition of this agent to FR regimen will improve progression free survival in patients with indolent NHL in first relapse. The...

Topo Target's Totect ( active ingredient is Dexrazoxane) is  a very ffective in treatment of extravasation from antracyclin drugs( Daunomycin, Adriamycin, Mitoxantrone, Epirubicin). Extravasation accidents are very very rare in this day and age of central lines/Port -a -caths and PICC lines. This...

Revlimid ( Celgene) is an oral agent already approved in US and EU countries for treatment of multiple Myeloma patients taht have failed at least one previous therapy. Approval in Switzerland is not surprising although it is a first for oral anti-cancer agents. The future would be in combination therapy...

YM bioscience Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) which has shown modest activity in pediatric patients with DIPG in Germany The proposed Phase II trial in US/Canada will explore the efficacy of this agent in terms of response...